Solid Tumor Targeting CAR-T Development Service through Fibrin Gel

Inadequate CAR-T cell infiltration, T-cell exhaustion, and the challenge posed by the blood–brain barrier (BBB) continue to limit therapeutic efficacy in solid tumor settings. Our Solid Tumor Targeting CAR-T Development Service through Fibrin Gel enables localized and sustained immunotherapy by delivering highly potent CAR-T cells within a custom-engineered, biocompatible fibrin matrix, supporting enhanced regional retention, improved cell viability, and more effective tumor engagement.

Introduction

CAR-T cell therapy has revolutionized hematologic cancer treatment, yet its application in solid tumors is hindered by the hostile TME, which limits T-cell infiltration, survival, and function. Regional administration of CAR-T cells bypasses the systemic challenges of IV infusion and promotes local drug concentrations. Our service is based on the superior performance of biomaterial platforms like fibrin gel, which functions as an in situ forming scaffold to accommodate and gradually release functional CAR-T cells into the tumor site.

Fig.1 Schematic illustration of CAR-T cells treating solid tumors via a hydrogel.¹

Creative Biolabs' Fibrin Gel Service

Traditional intravenous (IV) delivery of CAR-T cells often results in low tumor infiltration and rapid T-cell exhaustion due to systemic distribution and the hostile tumor microenvironment. Our specialized service provides a crucial bypass by enabling local, in situ formation of a CAR-T cell depot, resulting in significantly enhanced therapeutic persistence and tumor control, especially in post-surgical settings where residual disease is a major concern. We offer a precise methodology for developing, validating, and formulating your specific CAR-T construct within this advanced biomaterial platform.

The fibrin matrix can be applied to post-surgical tumor beds to help limit local recurrence, to dense or inoperable solid tumors to support deeper CAR-T infiltration, or to body cavities to achieve high local exposure with reduced systemic effects. The gel structure is tunable: a low-density formulation allows rapid CAR-T release for fast infiltration, while a denser, retention-focused matrix supports prolonged cell presence for sustained immune surveillance.

Discover How We Can Help - Request a Consultation.

What We Can Offer

How It Works

The final deliverables include an optimized fibrin gel protocol, an in vivo efficacy and persistence report with survival and tumor-infiltrating lymphocytes data, and functional release data demonstrating T-cell viability and cytokine secretion post-encapsulation.

Key Benefits

• Local Retention: Maintains a high CAR-T concentration at the tumor site.
• Enhanced Infiltration: Supports directional migration into solid tumor tissue.
• Reduced Systemic Exposure: Minimizes cytokine release and off-target toxicity.
• Fully Biodegradable: Naturally resorbed, no device removal required.

Related Services

FAQs

Partner with Us

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service through Fibrin Gel offers a validated, next-generation solution for overcoming the systemic delivery and persistence challenges in solid oncology. By combining cutting-edge CAR-T manufacturing with a customized, biocompatible fibrin biomaterial, we provide a localized, sustained, and highly efficacious delivery platform for your immunotherapy assets. Our expert team is ready to discuss your specific CAR construct and assist in developing a robust regional delivery system through our proprietary fibrin gel technology. Contact Our Team for More Information.

Reference

1. Wu, Shun-Yu, et al. "Delivering CAR-T Cells into Solid Tumors via Hydrogels." MedComm – Oncology, vol. 2, no. 3, Sept. 2023, pp. 143-54. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1002/mog2.40